(Q37162798)

18 August 2017

1 reference

title

A review of the association between antipsychotic use and hyperprolactinaemia (English)

1 reference

18 August 2017

Chris Bushe

1

1 reference

18 August 2017

Michael Shaw

series ordinal

2

1 reference

18 August 2017

Robert C Peveler

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Journal of Psychopharmacology

18 August 2017

1 reference

18 August 2017

22

1 reference

18 August 2017

2 Suppl

1 reference

18 August 2017

46-55

1 reference

Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics

18 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Risk of hip fracture in patients with a history of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Osteoporosis in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Sexual dysfunction in patients taking conventional antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Plasma prolactin concentrations and risk of postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Prolactin and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Dopamine antagonists and the development of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088435

21 January 2018

Identifiers

DOI

10.1177/0269881107088435

1 reference

18 August 2017

1 reference